Evidence map›Paper›PMID 40841102›Full record

ReviewJACC. CardioOncology2025

Cancer and Cardiovascular Disease: Shared Risk Factors, Mechanisms, and Clinical Implications: JACC: CardioOncology State-of-the-Art Review.

Laith Alhuneafat, Avirup Guha, Anne Blaes, Suma H Konety

Abstract readReview
In one paragraph

Review in JACC. CardioOncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Recent updates and perspectives in "Onco-hypertension".Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  4. Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  5. Review
  6. Review
  7. Impact of CaInternational journal of molecular sciences · 2026
    Review
  8. Determinants of cancer mortality in patients after acute myocardial infarction.International journal of cardiology. Heart & vasculature · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Research Priorities and Future Directions in Cardio-Oncology.Current treatment options in oncology · 2026
    Review
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laith AlhuneafatCardiovascular Division, University of Minnesota, Minneapolis, USA. Electronic address: https://twitter.com/Lalhuneafat.
Avirup GuhaCardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, Georgia, USA; Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.
Anne BlaesDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA.
Suma H KonetyCardiovascular Division, University of Minnesota, Minneapolis, USA. Electronic address: shkonety@umn.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer and cardiovascular disease (CVD) remain the leading causes of morbidity and mortality worldwide, with emerging evidence highlighting their complex and bidirectional interplay. Shared risk factors, including aging, systemic inflammation, metabolic dysregulation, and lifestyle behaviors, can contribute to their co-occurrence while underlying biological mechanisms such as oxidative stress, chronic inflammation, and clonal hematopoiesis further reinforce their connection. These mechanisms drive pathophysiological changes contributing to disease progression, increasing susceptibility to both conditions. This review explores the epidemiology, overlapping biological pathways, and risk factors linking cancer and CVD, emphasizing key mechanisms such as epigenetic modifications, immune system dysregulation, and cellular senescence. Future research should aim to identify biomarkers, refine risk models, and develop targeted strategies to mitigate disease burden and improve outcomes.

Indexed as

bidirectionalcancercardiovascular diseaseepigeneticsmechanismspathwaysreverse cardio-oncologyrisk factors

Identifiers

PMID40841102
PMCPMC12441630

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.